Peptides Hype, GLP-1 Therapies, and the Gray-Market Risks of DIY Injections

Podcast snapshot

In this Science Quickly edition, host Rachel Feltman talks with Victoria Song about the surge of interest in peptides, what GLP-1 drugs are, how gray-market sources and compounding pharmacies operate, and the policy and health risks tied to DIY injections and culture surrounding wellness, biotech, and medicine.

• "the science on that is far from settled" - Rachel Feltman
• GLP-1 therapies and the gray-market stakes are distinct from mainstream use - Victoria Song
• gray-market peptides are often labeled as "research only" material - Victoria Song
• NAD is Not a peptide, and misconceptions blur the line between skincare hype and biology - Victoria Song

Overview

The podcast, part of Scientific American's Science Quickly, examines the peptide craze that has infiltrated social media, wellness culture, and congressional hearings. While peptides are real chemical building blocks—short chains of amino acids—the episode emphasizes that the science behind many hype claims is unsettled, and the expansion of gray-market peptides raises safety concerns for people who inject themselves without medical supervision.

What are peptides

The discussion opens with a basic definition: peptides are short chains of amino acids, building blocks of proteins. The hosts describe how peptides have gained traction in the biohacking community and among wellness and fitness influencers who promote them as cures for a range of issues from pain to weight loss and skincare. The conversation emphasizes that popular narratives around peptides often outpace the underlying science, and that many online claims conflate peptides with injections that require medical oversight.

GLP-1, GLP-3, and retatrutide

The episode then delves into GLP-1 and a peptide referred to as GLP3, whose official name is retatrutide. Retatrutide is described as a triple agonist in late-stage FDA trials, potentially more effective than existing drugs like Tirzepatide. The guest, Victoria Song, explains how influencers have discussed these substances and how some market or disseminate information about them through gray-market channels to bypass prescriptions and regulatory barriers. She notes that retatrutide is not yet approved for weight loss and that Eli Lilly's trials are not expected to conclude until late 2026, underscoring the difference between clinically studied therapies and self-administered, unsupervised use.

"Retatrutide is currently under phase 3 FDA clinical trials by Eli Lilly. It is a triple agonist, which means it works on three different pathways." - Victoria Song

Gray-market peptides, compounding pharmacies, and sourcing

The hosts compare standard compounding pharmacies, which customize medications for patients with specific needs, to the gray-market peptides widely sold online for research purposes. They explain that the FDA allowed certain GLP-1 drugs to be produced by compounding pharmacies during shortages, but that the quality and regulation of some compounding networks vary widely. The conversation highlights the regulatory gray area around compounding, branding, and sourcing—including online sales that may label products as for laboratory use only, even when consumers obtain them for personal use. The discussion also touches on “Chinese peptides” marketed as research-only substances and the challenges in determining the provenance and purity of these products.

"These kind of gray market, dubiously sourced peptides, they are usually sold as, quote, unquote, research only." - Victoria Song

NAD, Goop, and peptide washing

The conversation then turns to wellness branding, noting that some products are labeled as peptide-rich or NAD-related, where NAD is not a peptide. Victoria Song critiques Gwyneth Paltrow's claims and the Goop Youth Boost NAD Cream for having only a trace amount of a peptide-related ingredient, while NAD itself is a coenzyme, not a peptide. The segment emphasizes the broader phenomenon of peptide-washing, where brands appropriate buzzy terminology to market products without delivering substantive peptide content.

"NAD is Not a peptide. NAD is nicotinamide adenine dinucleotide. You'll often see it marketed along with other peptides as nad, but it is not a peptide." - Victoria Song

Risks, scientific gaps, and the healthcare system

The discussion cautions about the risks of stacking or DIY peptide regimens, including toxicity from minerals (such as copper) and unknown long-term effects, given that most clinical research on GLP-1 agonists targets diabetes and obesity rather than broader self-treatment contexts. The host and guest discuss the frustration with the healthcare system as a driver of self-experimentation, where accessibility and cost barriers push people toward risky, unregulated sources. They emphasize that injections like GLP-1 therapies have real therapeutic potential but require careful evaluation of safety, dosing, and patient context.

Policy, RFK Jr., and future regulation

The episode covers a July FDA hearing about moving 14 peptides to an easier compounding list and RFK Jr.'s claim that the Biden administration labeled several peptides as unsafe for compounding. The guest clarifies that the FDA evaluates both safety and efficacy and that moving substances into category 1 bulk substances would permit broader compounding under express authorization. The discussion cautions against oversimplified narratives that mischaracterize agency roles and highlights the need for nuanced policy decisions that balance access, safety, and scientific integrity.

Conclusion

The podcast closes with an emphasis on nuance: peptides themselves are not inherently dangerous, but the current bioscience and medical ecosystems require careful handling, regulation, and clear communication. The host argues for a measured approach that recognizes legitimate medical uses, while avoiding hype or misinformation that can erode trust in institutions and patient safety.